[go: up one dir, main page]

PE20060558A1 - Conjugados para el diagnostico de enfermedades asociadas con angiogenesis que comprenden un ligante especifico para angiogenesis y una tintura de cianina - Google Patents

Conjugados para el diagnostico de enfermedades asociadas con angiogenesis que comprenden un ligante especifico para angiogenesis y una tintura de cianina

Info

Publication number
PE20060558A1
PE20060558A1 PE2005000843A PE2005000843A PE20060558A1 PE 20060558 A1 PE20060558 A1 PE 20060558A1 PE 2005000843 A PE2005000843 A PE 2005000843A PE 2005000843 A PE2005000843 A PE 2005000843A PE 20060558 A1 PE20060558 A1 PE 20060558A1
Authority
PE
Peru
Prior art keywords
angiogenesis
cyanine
diagnosis
specific binding
binding component
Prior art date
Application number
PE2005000843A
Other languages
English (en)
Inventor
Michael Schirner
Kai Licha
Christin Perlitz
Peter Hauff
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of PE20060558A1 publication Critical patent/PE20060558A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Materials For Medical Uses (AREA)

Abstract

REFERIDA A UN CONJUGADO DE FORMULA B-(D)n, DONDE B ES UN COMPONENTE LIGANTE ESPECIFICO PARA ANGIOGENESIS; D ES UNA TINTURA DE CIANINA; n ES 1, 2, 3, 4 O 5. EL COMPONENTE LIGANTE ESPECIFICO PARA ANGIOGENESIS SE SELECCIONA DE UN PEPTIDO, UNA PROTEINA, UN ACIDO NUCLEICO, UNA MOLECULA PEQUENA Y UN AZUCAR. LA PROTEINA SE SELECCIONA DE ENTRE UN FRAGMENTO DE UN ANTICUERPO, UN ANTICUERPO DE CADENA UNICA Y UN ANTICUERPO TAL COMO L19, E8, AP38, Y AP39. EL ACIDO NUCLEICO SE SELECCIONA DE ADN, ARN, APTAMEROS Y PNA; LA MOLECULA PEQUENA ES 2,2-DIFENILETILAMINA Y LA TINTURA DE CIANINA SE SELECCIONA DE CARBOCIANINA, DICARBOCIANINA Y TRICARBOCIANINA. DICHO COMPONENTE LIGANTE ESPECIFICO PARA ANGIOGENESIS SE DIRIGE CONTRA EL DOMINIO DE EB-D FIBRONECTINA. DICHO CONJUGADO ES UTIL PARA EL DIAGNOSTICO DE MICROMETASTASIS Y PEQUENAS LESIONES PROLIFERATIVAS, EN PARTICULAR, TUMORES PRIMARIOS, PRECANCEROSIS, METAPLASIA, LESIONES INFLAMATORIAS Y ENFERMEDADES OCULARES
PE2005000843A 2004-07-22 2005-07-21 Conjugados para el diagnostico de enfermedades asociadas con angiogenesis que comprenden un ligante especifico para angiogenesis y una tintura de cianina PE20060558A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04017375A EP1619501B1 (en) 2004-07-22 2004-07-22 Use of cyanine dyes for the diagnosis of disease associated with angiogenesis

Publications (1)

Publication Number Publication Date
PE20060558A1 true PE20060558A1 (es) 2006-07-26

Family

ID=34925879

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000843A PE20060558A1 (es) 2004-07-22 2005-07-21 Conjugados para el diagnostico de enfermedades asociadas con angiogenesis que comprenden un ligante especifico para angiogenesis y una tintura de cianina

Country Status (15)

Country Link
EP (3) EP1619501B1 (es)
JP (1) JP2008506747A (es)
KR (1) KR20070062973A (es)
CN (1) CN101022835A (es)
AR (1) AR050264A1 (es)
AT (1) ATE374367T1 (es)
AU (1) AU2005263638A1 (es)
CA (1) CA2573783A1 (es)
DE (1) DE602004009169D1 (es)
PA (1) PA8640201A1 (es)
PE (1) PE20060558A1 (es)
SV (1) SV2006002172A (es)
TW (1) TW200613733A (es)
UY (1) UY29029A1 (es)
WO (1) WO2006008179A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1679082A1 (en) * 2005-01-07 2006-07-12 Schering AG Use of cyanine dyes for the diagnosis of proliferative diseases
EP1743658A1 (en) * 2005-07-14 2007-01-17 Schering Aktiengesellschaft Optical imaging of rheumatoid arthritis
DE102007037008B4 (de) * 2007-08-06 2015-09-10 Siemens Aktiengesellschaft Diagnosesubstanz zur Anwendung in einem Verfahren zur Bestimmung der Aggressivität eines Prostatatumors
DE102007038730A1 (de) * 2007-08-16 2009-02-19 Carl Zeiss Meditec Ag Nachweis des menschlichen Vascular Endothelial Growth Factor
WO2009078970A1 (en) 2007-12-14 2009-06-25 Biotium, Inc. Fluorescent compounds
WO2009103312A1 (en) * 2008-02-19 2009-08-27 Ludwig-Maximilians-Universität Ezrin, serpin b5, peroxiredoxin-2 and heat shock protein beta-1 as autoantigens for psoriasis and poststreptococcal diseases
CN101518528B (zh) * 2008-02-29 2014-02-26 史春梦 一组碳花青染料类的近红外荧光化合物的用途
EP2393513B1 (en) * 2009-02-06 2016-10-19 The General Hospital Corporation Methods of treating vascular lesions
US20120226119A1 (en) * 2009-07-09 2012-09-06 Hoffmann-La Roche Inc. Vivo tumor vasculature imaging
US8658434B2 (en) 2009-10-28 2014-02-25 Biotium, Inc. Fluorescent pyrene compounds
GB0922014D0 (en) 2009-12-17 2010-02-03 Ge Healthcare Ltd Novel integrin binders
WO2014122228A1 (en) 2013-02-07 2014-08-14 Westfaelische Wilhelms-Universitaet Muenster Labelled compounds that bind to alpha-v-beta-3 integrin
JP6752582B2 (ja) * 2016-02-08 2020-09-09 キヤノン株式会社 光音響イメージング用造影剤
TWI617281B (zh) * 2017-01-12 2018-03-11 財團法人工業技術研究院 傷口狀態分析方法與系統
CN108410202A (zh) * 2018-02-12 2018-08-17 成都驷博生物科技有限公司 一种喹啉七甲川菁染料的制备方法
CN110201189B (zh) * 2019-06-03 2021-12-07 沈阳药科大学 白蛋白结合型近红外荧光染料-马来酰亚胺共轭物
CN112994990B (zh) * 2021-05-20 2021-07-30 蚂蚁金服（杭州）网络技术有限公司 一种环路检测方法、装置、电子设备与存储介质

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1144688A (en) * 1987-03-17 1988-09-15 Dana-Farber Cancer Institute, Inc. A pharmaceutical composition comprising cyanine dye
GB9708265D0 (en) * 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
DE19947559A1 (de) * 1999-09-24 2001-04-19 Schering Ag Antikörper-Farbstoffkonjugate gegen Zielstrukturen der Angiogenese zur intraoperativen Tumorranddarstellung
US6180086B1 (en) * 2000-01-18 2001-01-30 Mallinckrodt Inc. Hydrophilic cyanine dyes
JP2003524018A (ja) * 2000-02-24 2003-08-12 アイトゲネーシシェ テクニシェ ホッホシューレ チューリッヒ フィブロネクチンのｅｄ‐ｂドメインに特異的な抗体、前記抗体を含む複合体、および血管形成を検出および治療するためのその使用
CA2468081A1 (en) * 2002-01-03 2003-07-10 Schering Aktiengesellschaft Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours
CA2478414C (en) * 2002-03-11 2012-11-13 Philogen S.P.A. Selective targeting of tumor vasculature using antibody molecules
DE60323766D1 (de) * 2003-01-24 2008-11-06 Bayer Schering Pharma Ag En konjugate mit biomolekülen für fluoreszenzdiagnose
WO2006073314A1 (en) * 2005-01-06 2006-07-13 Ge Healthcare As Optical imaging
EP1679082A1 (en) * 2005-01-07 2006-07-12 Schering AG Use of cyanine dyes for the diagnosis of proliferative diseases

Also Published As

Publication number Publication date
TW200613733A (en) 2006-05-01
CA2573783A1 (en) 2006-01-26
EP1784226A2 (en) 2007-05-16
EP1816475A1 (en) 2007-08-08
KR20070062973A (ko) 2007-06-18
CN101022835A (zh) 2007-08-22
AR050264A1 (es) 2006-10-11
EP1619501A1 (en) 2006-01-25
WO2006008179A2 (en) 2006-01-26
SV2006002172A (es) 2006-02-15
AU2005263638A1 (en) 2006-01-26
PA8640201A1 (es) 2006-07-03
UY29029A1 (es) 2005-12-30
DE602004009169D1 (de) 2007-11-08
JP2008506747A (ja) 2008-03-06
WO2006008179A3 (en) 2007-01-11
ATE374367T1 (de) 2007-10-15
EP1619501B1 (en) 2007-09-26

Similar Documents

Publication Publication Date Title
PE20060558A1 (es) Conjugados para el diagnostico de enfermedades asociadas con angiogenesis que comprenden un ligante especifico para angiogenesis y una tintura de cianina
AR072680A1 (es) Axmi-115 axmi-113 axmi-005 axmi-163 y axmi-184 proteinas insecticidas y metodos de uso de las mismas
EP2117604A4 (en) METHOD AND COMPOSITION FOR IMPROVED F-18 MARKING OF PROTEINS, PEPTIDES AND OTHER MOLECULES
DK1597282T3 (da) Antistofmolekyler, der har specificitet for human IL-1 beta
MX358705B (es) Agentes de union de esclerostina.
ATE505489T1 (de) Tgf-beta-1-spezifische antikörper
CY1121580T1 (el) ΝΕΟΙ ΠΡΟΑΓΩΓΕΙΣ β-ΑΚΤΙΝΗΣ ΚΑΙ RPS21 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
EP1994142A4 (en) METHOD AND COMPOSITIONS FOR FAST ISOLATION OF SMALL RNA MOLECULES
NO20083062L (no) Humane monoklonale antistoffer mot fukosyl-GM1 og fremgangsmater for anvendelse av anti-fukosyl-GM1
UY26815A1 (es) Métodos para tratar enfermedades reumáticas al usar una molécula ctla4 soluble
NO20081987L (no) Humane, monoklonale antistoffer mot CD70
NO20081287A (no) Brenselsammensetning og fremgangsmåte for å fremstille denne
EA200701439A1 (ru) Pyy-агонисты и их применение
JP2011530537A5 (es)
CY1115212T1 (el) Διαμεσολαβηση στην κυτταροτοξικοτητα των κυτταρων που παρουσιαζουν eπιφaneiakh εκφραση της cd44
EA200600735A1 (ru) Нуклеиновые кислоты, специфично связывающие биоактивный грелин
CY1119568T1 (el) Περιοχη δεσμευσης της βακτηριακης ατρ συνθασης
BR112023023650A2 (pt) Composições e métodos relacionados a anticorpos ativados por tumores direcionados a egfr e antígenos de células efetoras
WO2006073429A3 (en) Entrapped binding protein as biosensors
EP1987165A4 (en) Gene with influence on the human memory
WO2005014723A8 (en) Cyanin-type compounds having an alkynyl linker arm
EP1864134A4 (en) METHOD FOR TREATING OR PREVENTING HORMONRESISTENT PROSTATE CANCER USING PROTOCADHERINE PC SPECIFIC SIRNA OR OTHER INHIBITORS OF PROTOCADHERINE PC EXPRESSION OR ACTIVITY
ATE523603T1 (de) Konjugatkomplexe zum analytnachweis
EA200801414A1 (ru) Кальцилитические соединения
AR062698A1 (es) Aptameros marcados con 68 ga

Legal Events

Date Code Title Description
FC Refusal